Abstract
Intravenous immune globulin (IVIG) therapy is given to replace low immune globulin stores and provide immune modulation.[1][1],[2][2] However, there is a lack of high-level evidence supporting its use, and serious adverse effects have been associated with IVIG therapy.[3][3]–[5][4] In September
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
